London, UK – [Date of Publication, e.g., November 27, 2023] – In a significant breakthrough that redefines our understanding of cancer progression, an international consortium of researchers has uncovered a critical link between age-related blood cell mutations and the aggressive behaviour of cancerous tumours. Scientists from the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have collaboratively demonstrated that the expansion of mutant blood cells, a phenomenon inherently tied to the ageing process, can infiltrate solid tumours, leading to markedly worse prognoses for patients, irrespective of their age or the stage of their cancer at diagnosis.
This groundbreaking research, published today in the prestigious New England Journal of Medicine, not only illuminates a previously unrecognised pathway by which ageing influences cancer evolution but also opens new avenues for therapeutic intervention and preventative strategies in an increasingly ageing global population. The findings suggest that the microscopic battles waged within our bodies as we age can directly impact our susceptibility to and survival from one of humanity’s most formidable diseases.
The Biological Interface of Ageing and Disease
The intersection of age-related genetic alterations and chronic diseases such as cancer and cardiovascular conditions represents a burgeoning field of medical inquiry. As global life expectancies continue to rise, so too does the prevalence of age-related disorders, placing immense pressure on healthcare systems and underscoring the urgent need for innovative preventative and therapeutic approaches. Understanding the intricate biological mechanisms that underpin this age-disease nexus is paramount to developing effective strategies that promote healthy ageing and mitigate the burden of age-associated illnesses.
A key player in this complex interplay is a condition known as Clonal Haematopoiesis of Indeterminate Potential, or CHIP. CHIP is characterised by the accumulation of somatic mutations in blood stem cells over time. These mutations lead to the clonal expansion of specific blood cell lineages, meaning that a particular mutant cell multiplies excessively, giving rise to a large population of genetically identical cells. The development of CHIP is influenced by a combination of advancing age and exposure to various environmental factors, acting as a silent, invisible clock ticking within our haematopoietic system.
Prior research has firmly established CHIP as a significant risk factor for a range of age-related health problems, most notably cardiovascular disease. Its association with conditions like atherosclerosis and heart failure has provided crucial insights into how subtle genetic changes in blood cells can exert systemic effects throughout the body. However, despite its known links to age-related pathologies, the precise impact of these age-related genetic changes on the evolution and prognosis of solid cancers – tumours arising from non-blood-forming tissues – had remained largely unexplored, representing a substantial gap in oncological knowledge. This new study now dramatically bridges that gap, offering unprecedented clarity into a previously obscure interaction.
Unveiling the CHIP-Cancer Connection: A Chronological Journey of Discovery
The journey to this pivotal discovery began with an ambitious, multi-faceted research endeavour, leveraging some of the most comprehensive cancer studies ever undertaken. The core of the investigation was built upon detailed analyses of over 400 patients with lung cancer, primarily drawn from the Cancer Research UK-funded TRACERx (Tracking Cancer Evolution through Therapy) and PEACE (Postmortem Examination of Advanced Cancer Environments) studies. These UK-based cohorts provided an invaluable depth of clinical and biological data, allowing researchers to meticulously track cancer evolution and its systemic interactions. To validate and broaden these initial findings, the team then collaborated with Memorial Sloan Kettering Cancer Center (MSK) in the US, accessing an enormous dataset encompassing 49,000 patients with a diverse array of cancer types. This two-pronged approach – deep dive into lung cancer followed by broad validation across numerous malignancies – lent immense statistical power and generalisability to their conclusions.
Initial Correlations: CHIP and Cancer Prognosis
The research team embarked on their investigation by conducting an initial examination of blood samples collected from the patient cohorts. This crucial step allowed them to precisely identify which patients harboured CHIP mutations in their circulating blood cells. Once this genetic fingerprint was established, the scientists meticulously matched these genetic profiles with corresponding clinical data, including patient demographics, cancer stage, treatment regimens, and, critically, patient survival outcomes.
The results of this initial analysis were striking and immediately pointed towards a significant correlation. Patients found to have CHIP mutations in their blood exhibited a consistently shorter overall survival period compared to those without CHIP. What made this finding particularly impactful was its independence from other well-established prognostic factors. The association between CHIP and reduced survival persisted regardless of the patient’s chronological age or the stage at which their cancer was diagnosed. This indicated that CHIP was not merely a passive marker of advanced age or disease but rather an active, independent factor influencing the trajectory of cancer. This initial observation served as a powerful impetus for the research team to delve deeper into the precise mechanisms underlying this concerning association.
The Critical Distinction: Tumour-Infiltrating Clonal Haematopoiesis (TI-CH)
Armed with the knowledge that CHIP was an independent predictor of adverse outcomes, the researchers intensified their investigation, seeking to understand how these systemic blood mutations exerted their influence on solid tumours. Their next step involved a more detailed study of patients with CHIP, focusing on whether these specific mutant blood cells were not just circulating in the bloodstream but were actively infiltrating the lung tumours themselves. The hypothesis was that if these mutant blood cells were migrating into the tumour microenvironment, they could potentially alter its biology and influence cancer progression.
Their meticulous analysis confirmed this hypothesis: a significant proportion – 42% – of patients with CHIP also had these specific mutant blood cells present within their lung tumours. This phenomenon was so distinct and critical that the researchers coined a new term for it: Tumour-Infiltrating Clonal Haematopoiesis, or TI-CH. This distinction proved to be profoundly important. The team discovered that it was not merely the presence of CHIP in the blood that was primarily associated with the greater risk of cancer relapse and cancer-related mortality, but rather the presence of TI-CH – the actual infiltration of these mutant cells into the tumour tissue. This finding suggested a direct and active role for these age-related blood mutations in shaping the tumour’s aggressiveness.
Supporting Data from the PEACE Study: Metastatic Links
Further robust support for the critical role of TI-CH emerged from samples obtained through the PEACE study. The PEACE study is a unique and invaluable post-mortem investigation designed to understand the intricacies of advanced cancer, particularly focusing on the sites where cancer has spread – the primary cause of cancer death. By examining metastatic tumours from these post-mortem samples, the research team was able to gain unprecedented insight into the genetic landscape of disseminated disease.
The findings from the PEACE study unequivocally reinforced the TI-CH hypothesis. The team discovered that metastatic tumours, which represent the most aggressive and life-threatening manifestation of cancer, frequently contained TI-CH mutations. This observation provided compelling evidence that the infiltration of age-related mutant blood cells is not just confined to primary tumours but also plays a role in the establishment and progression of distant metastases, further solidifying its association with poor patient outcomes and advanced disease.
Not All Mutations Are Equal: Delving into the Mechanisms
The discovery of TI-CH’s detrimental impact naturally led the researchers to question the underlying biological mechanisms. How exactly did these infiltrating mutant blood cells contribute to worse cancer outcomes? To unravel this mystery, the scientists turned their attention to the cellular composition of the lung tumours, performing detailed analyses to identify changes associated with TI-CH.
The Role of Myeloid Cells in the Tumour Microenvironment
Their investigations revealed a critical clue: patients with TI-CH exhibited a marked expansion of myeloid cells within their lung tumours. Myeloid cells are a type of immune cell, part of the innate immune system, and they represent a significant component of the tumour microenvironment – the complex ecosystem of cells, blood vessels, and signalling molecules that surrounds and interacts with cancer cells. This microenvironment is increasingly recognised as a crucial determinant of tumour growth, metastasis, and response to therapy.
Unlike some other immune cells, such as certain lymphocytes that are primed to recognise and directly fight cancer cells, myeloid cells often play a more ambivalent, and sometimes detrimental, role in the tumour microenvironment. While they are essential for immune responses, in the context of cancer, certain myeloid cell subsets have been shown to regulate inflammation in ways that can inadvertently support tumour progression, promote angiogenesis (new blood vessel formation), suppress anti-tumour immunity, and even facilitate cancer cell spread. The expansion of these myeloid cells within TI-CH positive tumours therefore provided a plausible mechanistic link between the mutant blood cells and increased tumour aggressiveness.
The TET2 Gene: A Key Regulator in Tumour Infiltration
Further investigation into the specific genetic landscape of CHIP and TI-CH revealed another crucial detail: the prominence of mutations affecting a gene called TET2. The TET2 gene is a vital regulator of blood cell production and function. It encodes an enzyme that plays a critical role in epigenetics, influencing gene expression without altering the underlying DNA sequence. Specifically, TET2 is involved in DNA demethylation, a process important for normal blood cell differentiation and function. Mutations in TET2 are among the most common alterations observed in CHIP.
The researchers discovered that among thousands of individuals studied, blood cells carrying TET2 mutations were significantly more likely to infiltrate tumours. To confirm this at a granular level, they performed single-cell analysis on hundreds of individual cells isolated directly from the tumours of two patients with TI-CH. This high-resolution analysis unequivocally demonstrated that TET2 mutations were predominantly present within the myeloid cell population, rather than in other types of immune cells within the tumour. This finding strongly implicated TET2-mutant myeloid cells as the primary culprits driving the detrimental effects of TI-CH.
Experimental Validation: TET2 Mutant Myeloid Cells Accelerate Tumour Growth
To move beyond correlation and establish a direct functional link, the team collaborated with blood cancer and CHIP experts at the Crick lab led by Dominique Bonnet. This collaboration facilitated experimental studies designed to directly assess the impact of TET2 mutations. They developed sophisticated in vitro models, growing "organoids" – mini lung tumours that recapitulate many features of real tumours – and co-cultured them with TET2 mutant myeloid cells.
The experimental results provided compelling functional evidence. They demonstrated that the presence of TET2 mutant myeloid cells profoundly remodelled the tumour microenvironment of the organoids. Crucially, these mutant cells also significantly accelerated tumour organoid growth. This direct experimental validation strongly supported the hypothesis that TET2-mutant myeloid cells are not just bystanders but active promoters of tumour progression, providing a clear functional mechanism for the observed clinical outcomes.
Looking Beyond Lung Cancer: Broad Validation and Implications
The extensive work on lung cancer and the mechanistic insights gained provided a robust foundation, but the researchers recognised the importance of validating these findings across a broader spectrum of malignancies. In collaboration with their colleagues at Memorial Sloan Kettering Cancer Center in the US, the team embarked on an ambitious validation study utilising an immense dataset of over 49,000 patients diagnosed with various types of cancer.
The results from this large-scale validation study were unequivocal: the presence of TI-CH emerged as an independent predictor of shorter overall survival across this diverse patient cohort. This powerful confirmation underscored the general applicability of their initial findings and suggested that the phenomenon of TI-CH is not limited to lung cancer but represents a widespread mechanism impacting cancer prognosis across many tumour types.
While TI-CH was broadly associated with worse outcomes, the study also revealed interesting variations in the prevalence of CHIP and TI-CH across different cancer types. Researchers observed that these age-related mutant blood cell infiltrations were significantly more common in cancers known for their aggressive nature and inherent resistance to treatment, such as lung cancer (where the initial discoveries were made), head and neck cancer, and pancreatic cancer. This correlation suggests that TI-CH might be a contributing factor to the notoriously poor prognoses associated with these particular malignancies, potentially explaining some of their refractory characteristics.
Future Directions and Transformative Implications
This landmark study represents a significant step forward in our understanding of the complex interplay between ageing and cancer. However, the researchers are quick to emphasise that this is just the beginning. The next crucial steps in this work will involve moving beyond association to definitively confirm that CHIP directly contributes to adverse cancer outcomes, and then to meticulously detail the exact molecular and cellular mechanisms by which CHIP is functionally implicated in the development and progression of aggressive cancers. This will involve delving deeper into the signalling pathways activated by TET2-mutant myeloid cells, their interactions with cancer cells, and their influence on the broader immune landscape of the tumour.
The implications of these findings are profound and far-reaching, potentially transforming various aspects of oncology:
- Improved Prognostication: The identification of TI-CH as an independent predictor of shorter survival could lead to the development of new diagnostic tools or biomarkers. Detecting TI-CH in cancer patients could allow clinicians to more accurately risk-stratify individuals, identifying those who require more aggressive treatment strategies or closer monitoring.
- Targeted Therapies: Understanding the specific role of TET2-mutant myeloid cells and their impact on the tumour microenvironment opens the door for novel therapeutic interventions. Strategies aimed at targeting these specific myeloid cells, modulating their inflammatory responses, or reversing their tumour-promoting effects could represent entirely new classes of cancer therapies, especially for patients with TI-CH.
- Preventative Strategies: Given that CHIP is an age-related phenomenon, this research might eventually lead to strategies for its early detection and even prevention or mitigation before cancer develops or progresses. Interventions aimed at slowing the expansion of CHIP clones or modifying the behaviour of mutant blood cells could become a vital component of future cancer prevention programmes, particularly for an ageing population.
- Personalised Medicine: The presence or absence of TI-CH could become another crucial factor in guiding personalised cancer treatment decisions, moving towards an era where therapies are precisely tailored to an individual’s unique genetic and immunological profile.
- Understanding Ageing: Beyond cancer, this research deepens our understanding of how ageing processes at a cellular level contribute to systemic disease, potentially offering insights into other age-related conditions.
Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author on the study, articulated the significance of the findings: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." His statement underscores the pervasive nature of CHIP and the critical need to consider its influence in oncological contexts.
Echoing this sentiment, Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, highlighted the novelty and future potential: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations,’ age-related CHIP and cancer, providing insight into how ageing might impact cancer risk. As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." Swanton’s vision points towards a future where understanding the nuances of ageing at a cellular level could unlock entirely new paradigms for cancer management and prevention.
This monumental work was made possible through the generous support of key funders, including Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional vital contributions. Such large-scale, collaborative research efforts are indispensable for tackling the most complex challenges in human health, paving the way for discoveries that promise to transform patient care and public health in the decades to come. The identification of TI-CH marks a pivotal moment, urging the scientific community to integrate the biology of ageing more deeply into the fight against cancer.
About the Author
